COMPANY
Clinical Phase 2
Profile checked Oct 10, 2026
Keywords: Amyotrophic Lateral Sclerosis TRCN-1023
Timeline
- Trial start Phase 1/Phase 2: FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS source ↗
- Raise Private equity round — Series A: $101M (total, as published), announced Nov 12, 2024. Source: company's own press page. source ↗
Upcoming milestones
- 2027-09 (ESTIMATED) · Phase 1/Phase 2 · FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS · NCT07674667
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $101.0M. Last 2 years.
- Private equity round — Series A: $101M (total, as published), announced Nov 12, 2024. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT07674667 | FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | Phase 1/Phase 2 | Recruiting | Aug 20, 2026 | 2027-09 (estimated) |
Raises and investors new
Form D raises come from the company’s own SEC filing (last 2 years).
- InvestorListed in the portfolio of Atlas Venture (captured Oct 12, 2026). portfolio page ↗
